Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438853 · ClinicalTrials.gov registry record · Phase 1
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
A Phase 1 study of Sepsis and Acute Respiratory Distress Syndrome, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT01438853 is a Phase 1 study of Sepsis and Acute Respiratory Distress Syndrome that has completed, run by Altor BioScience. The registered enrollment target is 18 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT01438853, a Phase 1 study of Sepsis and Acute Respiratory Distress Syndrome, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
This Phase I/IIa, multi-center, randomized, placebo-controlled, single-blinded dose-escalation study evaluated TNX-832 (also referred to as ALT-836 and Sunol cH36) in subjects with suspected or proven bacteria-induced ALI/ARDS. Up to five cohorts of at least six subjects each were originally planned. Subjects were to be randomized in a 5:1 ratio to receive TNX-832 or placebo,respectively, administered as a single bolus infusion over 15 minutes. Three cohorts of subjects were enrolled to the study and safety and pharmacokinetics of the study treatment were evaluated.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL TNX-832
Study Locations (7)
Florida
- University of Miami - Miami
Massachusetts
- Beth Israel Deconess Medical Center - Boston
Missouri
- Washington University - St Louis
North Carolina
- Wake Forest University - Winston-Salem
Ohio
- Akron General Medical Center - Akron
Texas
- Baylor School of Medicine - Houston
Nova Scotia
- Capital Health - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01438853
The ClinicalTrials.gov registry entry for NCT01438853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (100% lower). The listed sponsor is Altor BioScience, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01438853 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Florida, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT01438853 about?
NCT01438853 is a clinical study titled "Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome". This Phase I/IIa, multi-center, randomized, placebo-controlled, single-blinded dose-escalation study evaluated TNX-832 (also referred to as ALT-836 and Sunol cH36) in subjects with suspected or proven bacteria-induced ALI/ARDS. Up to five cohorts of at least six subjects each were originally planned...
What is the current status of trial NCT01438853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2004-12. Estimated completion is 2008-02.
What conditions does trial NCT01438853 study?
This clinical trial studies the following conditions: Sepsis, Acute Respiratory Distress Syndrome, Acute Lung Injury.
What interventions are being tested in trial NCT01438853?
The interventions under investigation include: Placebo (DRUG), TNX-832 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01438853?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01438853 being conducted?
This trial has 7 study locations across Florida, Massachusetts, Missouri, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention
RECRUITING · Phase 1
-
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
ACTIVE NOT RECRUITING · Phase 1
-
Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance
COMPLETED · Phase 1
-
Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
COMPLETED · Phase 1
-
Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections
COMPLETED · Phase 1
-
The APS Phenotyping Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.